Skip to main content
PolicySpeak
← The ranking

Side by side

Compare organizations

Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

INR
INRAE

Academic / research · France

3
files engaged
of 583 tracked
3
positions filed
in those 583 files
declared FTE
self-declared
EP accreditations
as declared to the register
EFP
EFPIA

Industry association · Belgium

35
files engaged
of 583 tracked
49
positions filed
in those 583 files
13.4
declared FTE
self-declared
13
EP accreditations
as declared to the register

Declared costs: €6M+ a year · in the register since 2009

Files both filed on (2)

Medicinal products for human use · Evaluation of EU rules for users of genetic resources and the sharing of benefits arising from their utilization

Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.

What each said, in their own words

Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.

Medicinal products for human use

EFPIA · filed 27 Apr 2021 · source

EFPIA supports an agile regulatory framework and a strong incentives’ system that embrace and encourage advances in science, technology & medicines. This evaluation is an opportunity to implement learnings from COVID-19 and ensure a competitive, world-class regulatory system in Europe supporting a globally competitive research-based industry at a critical time.

EFPIA · filed 3 Oct 2023 · source

EFPIA supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.

EFPIA · filed 9 Oct 2023 · source

EFPIA supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.

INRAE · filed 7 Nov 2023 · source

Introduction Inrae is the French Public Research Institute for Agriculture, Food and the Environment. It has had a leading position in the development of microbiome science and its application for human, animal and plant health.

Evaluation of EU rules for users of genetic resources and the sharing of benefits arising from their utilization

INRAE · filed 11 Feb 2026 · source

INRAE is a French public research institution which carries out, for the most part, basic research activities with no commercial objective in the field of agriculture, food and the environment, using public and private funding and national and international collaborations.

Filed in French · English published by the European Commission

EFPIA · filed 11 Feb 2026 · source

EFPIA, representing the biopharmaceutical industry operating in Europe, welcomes the opportunity to contribute to the European Commission's open consultation on the EU Access and Benefit-Sharing (ABS) Regulation (EU No 511/2014).

Take this comparison with you

2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.